rTMS as an Intervention for Levodopa-induced Dyskinesia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorDanish Research Centre for Magnetic Resonance

About this trial

The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.

Eligibility criteria

Qualifiers

Clinically established or probable PD

Clinical Diagnostic Criteria for Parkinson's Disease

Peak-of-dose levodopa-induced dyskinesia.

Stable antiparkinsonian medicine for at least four weeks.

Disqualifiers

Psychiatric disorders.

Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin).

Regular usage of benzodiazepines and opioids (more than once per week).

History of neurological disease other than Parkinson's disease.

Trial design

Treatments tested in this trial

  • active TMS
  • sham TMS

Treatment groups

68 Participants
are divided into 4 treatment groups